Barboval drops for oral administration 25ml №1

Name:
Bubbling to-whether d / vn.prim.v vil.25ml in pack No. 1
Description:
Transparent colorless liquid with a specific aromatic odor. The main active ingredient is absent Form of release drops Dosage 1 ml of the drug (21 drops) contains ethyl ester of a-bromizovaleric acid 18 mg Special instructions Hypnotics and sedatives. Barbiturates in combination with other drugs. ATC code N05C B02. PharmacodynamicsBarboval® is a combined drug, the action of which is due to the properties of its constituent substances. Ethyl ester of α-bromoisovaleric acid has a calming effect due to a decrease in reflex excitability in the central parts of the nervous system and an increase in inhibition phenomena in the neurons of the cortex and subcortical structures of the brain. Phenobarbital suppresses the activating influence of the centers of the reticular formation of the middle and medulla oblongata on the cerebral cortex. The decrease in activating effects has a sedative, tranquilizing or hypnotic effect depending on the dose. A solution of menthol in the menthol ester of isovaleric acid has a sedative and moderate reflex vasodilating effect due to irritation of sensitive nerve endings. Pharmacokinetics Phenobarbital when taken orally is absorbed completely, slowly. The onset of Cmax is 1-2 hours, the connection with plasma proteins is about 50%. Metabolized in the liver, induces microsomal liver enzymes CYP3A4, CYP3A5 and CYP3A7 (the rate of enzymatic reactions increases 10-12 times). It accumulates in the body. In adults, T 1/2 is 3-4 days. It is excreted by the kidneys in the form of inactive metabolites, 25-50% – unchanged. It penetrates well through the placenta. Bromine (a component of ethyl bromisovalerianate) is absorbed when taken orally, if the doses are exceeded, it can accumulate, and is very slowly excreted from the body. Indications for use Symptomatic treatment of neurasthenia; short-term use for sleep disorders. The drug is indicated for short-term use, because the effectiveness of therapy after two weeks of taking the drug decreases and there is a risk of dependence. Dosage and administration Barboval® is taken orally with a small amount of liquid, 10-15 drops 2-3 times a day before meals. Doses and duration of treatment are set by the doctor individually. Taking the drug for more than 2 weeks is not recommended, because. its effectiveness after two weeks of therapy is reduced and there is a risk of developing physical and mental dependence. Use during pregnancy and lactation Taking phenobarbital during pregnancy may cause fetal abnormalities. After oral administration, phenobarbital crosses the placental barrier and is distributed to all tissues of the fetus, high concentrations are determined in the placenta, liver and brain. If phenobarbital was taken during pregnancy or if pregnancy occurred while taking phenobarbital, the patient should be informed of the potential hazard to the fetus. When taking phenobarbital to a nursing mother, phenobarbital in small amounts is excreted in breast milk. The drug is contraindicated in pregnant women and women who are breastfeeding. Precautions Taking phenobarbital can be habit-forming. Tolerance, mental and physical dependence may develop after prolonged use of the drug. As tolerance to phenobarbital develops, the dose required to maintain the same level of effect increases. It should be avoided prescribing the drug to patients with depressive disorders, suicidal tendencies, people with drug addiction. Elderly and debilitated patients may respond to phenobarbital by developing marked agitation, depression, and confusion. Caution should be exercised when prescribing phenobarbital to patients with acute or chronic pain because paradoxical arousal may develop and important clinical symptoms may be masked. While taking the drug, you should avoid drinking alcoholic beverages. The drug contains 65.85% (v / v) ethanol, that is, 0.266-0.399 g of 96% ethanol per single dose (10-15 drops). There have been reports of the development of life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) with the use of drugs containing phenobarbital. Very often, a life-threatening skin rash is accompanied by flu-like symptoms. If symptoms of skin reactions appear, the drug should be stopped immediately and consult a doctor. These patients should no longer resume the use of the drug Barboval®. Contraindications Hypersensitivity to the components of the drug, bromine; renal and / or liver failure; porphyria, pregnancy, lactation, children under 18 years of age. Due to the content of ethanol, Barboval® is contraindicated in patients with alcoholism, epilepsy, traumatic brain injury and other brain diseases with a decrease in the seizure threshold. Composition 1 ml of the drug (21 drops) contains ethyl ester of a-bromizovaleric acid 18 mg; a solution of menthol in the menthol ester of isovaleric acid (validol) 80 mg, phenobarbital 17 mg; excipients: sodium acetate trihydrate, ethanol (96%), purified water. The medicinal product contains 65.85% (v/v) ethanol 96%. Overdose Overdose is possible with frequent or prolonged use of the drug, which is associated with the cumulation of its components. Prolonged and constant use causes addiction, withdrawal symptoms, psychomotor agitation. Abrupt discontinuation of the drug may cause a withdrawal syndrome. Overdose symptoms: depression of the central nervous system, confusion, dizziness, ataxia, drowsiness, up to deep sleep. In severe cases of poisoning – respiratory failure, tachycardia, arrhythmias, lowering blood pressure, collapse, coma. Treatment: symptomatic. With the development of symptoms of acute overdose, it is necessary to maintain the vital functions of the body and conduct detoxification therapy, resuscitation may be required. Side effects The development of the following adverse reactions is possible: on the part of the digestive tract: constipation, a feeling of heaviness in the epigastric region, with prolonged use – impaired liver function, nausea, vomiting; from the nervous system: weakness, ataxia, impaired coordination of movements, nystagmus, hallucinations, paradoxical arousal, decreased concentration, fatigue, slow reactions, headache, cognitive impairment, confusion, drowsiness, mild dizziness; from the side of the cardiovascular system: arterial hypotension, bradycardia, fainting; on the part of the hematopoietic organs: anemia, thrombocytopenia, agranulocytosis; from the immune system: hypersensitivity reactions, including angioedema, allergic reactions (including skin rash, itching, urticaria); from the skin and mucous membranes: Stevens-Johnson syndrome, toxic epidermal necrolysis; on the part of the musculoskeletal system: with prolonged use of drugs containing phenobarbital, there is a risk of impaired osteogenesis; from the respiratory system: hypoventilation, apnea. Long-term use of drugs containing bromine can lead to bromine intoxication, which is characterized by such symptoms: depression of the central nervous system, depressed mood, confusion, ataxia, apathy, conjunctivitis, rhinitis, lacrimation, acne or purpura. In the event of adverse reactions, including those not listed in this leaflet, you should stop taking the drug and consult a doctor. Buy Barboval drops for oral administration 25ml №1 Price for Barboval drops for oral administration 25ml №1Instruction for use for Barboval drops for oral administration 25ml №1